

Table S1. Landmark sensitivity of the standardized mortality ratio.

Stratum	No landmark	3-month landmark	6-month landmark
<50	2.89 (2.44-3.40)	2.87 (2.42-3.38)	2.81 (2.37-3.32)
50-59	1.14 (1.03-1.25)	1.13 (1.02-1.24)	1.10 (0.99-1.21)
60-69	1.21 (1.14-1.28)	1.20 (1.13-1.26)	1.17 (1.10-1.23)
70-85	1.13 (1.09-1.16)	1.12 (1.08-1.15)	1.09 (1.06-1.13)
Total (age-standardized)	1.16 (1.13-1.19)	1.15 (1.12-1.18)	1.12 (1.09-1.15)
n	255,731	255,206	253,945
Observed CSM deaths	6250	6187	6045

Abbreviations: CSM, cardiovascular-specific mortality; CI, confidence intervals.

Table S2. Landmark sensitivity of cumulative incidence (overall cohort).

Outcome (month)	No landmark	3-month landmark	6-month landmark
CSM			
36 months	0.84	0.81	0.76
60 months	1.61	1.60	1.55
84 months	2.53 (2.47-2.59)	2.51 (2.45-2.57)	2.46 (2.39-2.53)
BCSM			
36 months	3.09	3.06	2.96
60 months	5.35	5.31	5.22
84 months	7.16	7.12	7.04
OCM			
36 months	2.1	2.06	1.95
60 months	4.06	4.03	3.92
84 months	6.28	6.25	6.14

Abbreviations: BCSM, breast cancer-specific mortality; CSM, cardiovascular-specific mortality; OCM, other cause mortality; CI, confidence intervals.

Table S3. Landmark sensitivity of the 70-85 crossover.

Quantity	No landmark	3-month landmark	6-month landmark
CSM cumulative incidence at 84 months (%)	6.98	6.92	6.82
BCSM cumulative incidence at 84 months (%)	7.75	7.68	7.49
Crossover			
CSM overtakes BCSM	97 months (~8.1 years)	97 months (~8.1 years)	96 months (~8 years)
95% CI (bootstrap)	91-101 months	91-102 months	90-100 months

Abbreviations: BCSM, breast cancer-specific mortality; CSM, cardiovascular-specific mortality; CI, confidence intervals.

